Phase 1 Trial | Zilebesiran demonstrates potential as prolonged-action hypertension therapeutic
21 Jul, 2023 | 13:32h | UTCZilebesiran, an RNA Interference Therapeutic Agent for Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Experimental Shot Given Every Six Months Controlled High Blood Pressure in Early Trial – HealthDay